Program Schedule

2
Antimicrobial Agents: What is New and What is New in the Old

Wednesday, October 8, 2014: 1:30 PM-3:30 PM
Room: The Pennsylvania Convention Center: 103-ABC
Co-organized with the Society of Infectious Diseases Pharmacists

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the use of previously-approved antibiotics for emerging infections
  • identify the potential utility for antibiotics in development
  • discuss the clinical applications of antimicrobial agents that have recently become available and what is newly understood about older agents

Target Audience: Scientists, Researchers, Pharmacists, Nurses, Microbiologists, Members-in-training, Medical students and residents, Investigators, Infectious diseases physicians, Infectious diseases pediatricians, Hospital administrators, Health care workers, Fellows, Clinicians, Academicians

Tracks: Pediatric ID, Investigative ID, Global ID, Adult ID

Moderators:  David Andes, MD, University of Wisconsin and Sujata Bhavnani, PharmD, Institute for Clinical Pharmacodynamics (ICPD)

Presentations:
2:00 PM
6
What is New?
Helen Boucher, MD, FIDSA
2:30 PM
7
What is in the Pipeline?
Michael Dudley, PharmD

CME Credits: Maximum of 2 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 2.0 knowledge-based contact hours (0.2 CEU) of pharmacy CE

ACPE Number: 0221-9999-14-089-L01-P

Disclosures:

D. Andes, Astellas: Consultant and Grant Investigator, Consulting fee and Research grant
Actelion: Grant Investigator, Research grant
Scynexis: Consultant, Consulting fee
Cubist: Consultant and Grant Investigator, Consulting fee and Research grant
Merck: Consultant, Consulting fee

S. Bhavnani, None

E. Ellis-Grosse, Astra-Zeneca: Consultant, Consulting fee
Cerexa/Forest: Consultant, Consulting fee
Fedora: Consultant, Consulting fee
Cempra: Consultant, Consulting fee
Rempex: Consultant, Consulting fee
Wockhardt: Consultant, Consulting fee
Wyeth/Pfizer: Shareholder, shareholder
Zavante: Board Member and Shareholder, shareholder
Kalyra: Consultant, Consulting fee

H. Boucher, None

M. Dudley, The Medicines Company: Employee, Salary

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. EDT, Oct. 8th with the exception of research findings presented at the IDWeek press conferences.

Sponsoring Societies:

© 2014, idweek.org. All Rights Reserved.

Follow IDWeek